Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00057369
Recruitment Status : Unknown
Verified June 2003 by Vicuron Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : April 2, 2003
Last Update Posted : June 24, 2005
Sponsor:
Information provided by:
Vicuron Pharmaceuticals

Brief Summary:
This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.

Condition or disease Intervention/treatment Phase
Bacteremia Drug: dalbavancin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens
Study Start Date : February 2001
Study Completion Date : June 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Dalbavancin





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • The patient or his/her legally authorized representative has given informed consent by means approved by the investigator's IRB/EC;
  • > 18 years of age;
  • Had one or more central venous catheters at the time initial signs of infection were evident;
  • Creatinine clearance <50 mL/min;
  • Bilirubin > 2x the upper limit of normal;
  • Treatment with an antibiotic effective against Gram-positive bacterial infections for more than 24 hours within 48 hours of study medication initiation,
  • Prolonged antibiotic therapy for CR-BSI anticipated (i.e., >2 weeks)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00057369


Locations
Layout table for location information
United States, Georgia
Wellstar/Kennestone Hospital
Marietta, Georgia, United States, 30060
Sponsors and Collaborators
Vicuron Pharmaceuticals
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00057369    
Other Study ID Numbers: VER001-4
First Posted: April 2, 2003    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: June 2003
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacteremia
Sepsis
Infections
Bacterial Infections
Bacterial Infections and Mycoses
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Dalbavancin
Anti-Bacterial Agents
Anti-Infective Agents